Article
Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients.
Melanoma research - 1 Oct 2022
Ostojic Nikola, Radevic Tatjana, Kandolf Sekulovic Lidija, Djordjevic Boban, Jaukovic Ljiljana, Stepic Nenad, Supic Gordana
Abstract excerpt
Melanoma is one of the most aggressive tumors, and in the setting of rising incidence and mortality, there is an urgent need to identify new prognostic markers. Toll-like receptors (TLRs), are aberrantly expressed in numerous cancers, including melanoma. TLR signaling provides a microenvironment that is involved in antitumor immune response, chronic inflammation, cancer cell proliferation and evasion of immune...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.